Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Treatment of COVID-19 in Hospitalized Patients
Latest Information Update: 04 Jul 2022
Price :
$35 *
At a glance
- Drugs Telmisartan (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms INTEL
- 27 Jun 2022 Status changed from recruiting to discontinued.
- 03 Sep 2021 Status changed from not yet recruiting to recruiting.
- 21 Jan 2021 New trial record